Cantor Fitzgerald Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST)

Stock analysts at Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research report issued on Tuesday, MarketBeat.com reports. The firm set an “overweight” rating and a $17.00 price target on the stock. Cantor Fitzgerald’s target price points to a potential upside of 391.33% from the company’s previous close.

Several other research firms have also issued reports on AQST. JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. Finally, Leerink Partners raised their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $3.46 on Tuesday. The company has a market cap of $315.48 million, a price-to-earnings ratio of -7.69 and a beta of 2.62. Aquestive Therapeutics has a one year low of $1.84 and a one year high of $6.23. The firm has a fifty day moving average price of $4.79 and a two-hundred day moving average price of $4.07.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter in the prior year, the business posted ($0.03) EPS. Equities research analysts expect that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC bought a new position in shares of Aquestive Therapeutics in the third quarter worth approximately $28,000. Victory Capital Management Inc. bought a new stake in shares of Aquestive Therapeutics in the second quarter worth approximately $27,000. Harvey Capital Management Inc. purchased a new position in shares of Aquestive Therapeutics during the third quarter valued at approximately $88,000. Intech Investment Management LLC purchased a new stake in Aquestive Therapeutics in the third quarter worth approximately $90,000. Finally, BNP Paribas Financial Markets increased its position in Aquestive Therapeutics by 252.2% during the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock valued at $94,000 after acquiring an additional 13,481 shares during the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.